|
Antiarrhythmic agents are a group of pharmaceuticals that are used to suppress abnormal rhythms of the heart (cardiac arrhythmias), such as atrial fibrillation, atrial flutter, ventricular tachycardia, and ventricular fibrillation. Many attempts have been made to classify antiarrhythmic agents. The problem arises from the fact that many of the antiarrhythmic agents have multiple modes of action, making any classification imprecise. == Singh Vaughan Williams classification == The Singh Vaughan Williams classification was introduced in 1970. As a doctoral candidate at Oxford University working in the lab of Vaughan Williams, Dr. Bramah Singh determined that amiodarone and sotalol had antiarrhythmic properties and belonged to a new class of antiarrhythmic agents (what would become the class III antiarrhythmic agents). See Singh BN, Vaughan Williams EM (1970). "The effect of amiodarone, a new anti-anginal drug, on cardiac muscle". Br. J. Pharmacol. 39 (4): 657–67. doi:10.1111/j.1476-5381.1970.tb09891.x. PMC 1702721. PMID 5485142. With regards to management of atrial fibrillation, Class I and III are used in rhythm control as medical cardioversion agents while Class II and IV are used as rate control agents. There are five main classes in the Singh Vaughan Williams classification of antiarrhythmic agents: * Class I agents interfere with the sodium (Na+) channel. * Class II agents are anti-sympathetic nervous system agents. Most agents in this class are beta blockers. * Class III agents affect potassium (K+) efflux. * Class IV agents affect calcium channels and the AV node. * Class V agents work by other or unknown mechanisms. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「antiarrhythmic agent」の詳細全文を読む スポンサード リンク
|